메뉴 건너뛰기




Volumn 30, Issue 6, 2012, Pages 954-961

Calcium supplementation and kidney stone risk in osteoporosis: A systematic literature review

Author keywords

Calcium supplementation; Kidney calculi; Nephrolithiasis; Osteoporosis; Renal colic

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; CALCIUM CARBONATE; CONJUGATED ESTROGEN; ESTRADIOL PLUS ESTRIOL; ESTRADIOL PLUS ESTRIOL PLUS NORETHISTERONACETATE; ESTROGEN; ETIDRONIC ACID; HYDROCHLOROTHIAZIDE; LIOTHYRONINE; MEDROGESTONE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PROGESTERONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VITAMIN D;

EID: 84872689043     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (22)

References (63)
  • 1
    • 2942744520 scopus 로고    scopus 로고
    • Withdrawn Calcium supplementation on bone loss in postmenopausal women
    • Shea B, Wells G, Cranney A et al. Withdrawn Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2004, (1): CD004526.
    • (2004) Cochrane Database Syst Rev , Issue.1
    • Shea, B.1    Wells, G.2    Cranney, A.3
  • 2
    • 77952374262 scopus 로고    scopus 로고
    • Long-term effect of the Women's Health Initiative study on antiosteoporosis medication prescribing
    • Lee E, Maneno MK, Wutoh AK, Zuckerman IH. Long-term effect of the Women's Health Initiative study on antiosteoporosis medication prescribing. J Womens Health (Larchmt) 2010; 19: 847-54.
    • (2010) J Womens Health (Larchmt) , vol.19 , pp. 847-854
    • Lee, E.1    Maneno, M.K.2    Wutoh, A.K.3    Zuckerman, I.H.4
  • 3
    • 0036963450 scopus 로고    scopus 로고
    • Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
    • Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 985-92.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 985-992
    • Johnell, O.1    Scheele, W.H.2    Lu, Y.3    Reginster, J.Y.4    Need, A.G.5    Seeman, E.6
  • 4
    • 80054073920 scopus 로고    scopus 로고
    • Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis a meta-analysis
    • Von Keyserlingk C, Hopkins R, Anastasilakis A et al. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis a meta-analysis. Sem Arthritis Rheum 2011; 41: 178-86.
    • (2011) Sem Arthritis Rheum , vol.41 , pp. 178-186
    • Von Keyserlingk, C.1    Hopkins, R.2    Anastasilakis, A.3
  • 5
    • 0024311395 scopus 로고
    • Effect of salcatonin given intranasally on early postmenopausal bone loss
    • Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989; 299: 477-9.
    • (1989) BMJ , vol.299 , pp. 477-479
    • Overgaard, K.1    Riis, B.J.2    Christiansen, C.3    Hansen, M.A.4
  • 6
    • 21044447888 scopus 로고    scopus 로고
    • Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis Treatment of Peripheral Osteoporosis (TROPOS) study
    • Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-22.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 2816-2822
    • Reginster, J.Y.1    Seeman, E.2    De Vernejoul, M.C.3
  • 7
    • 0035837553 scopus 로고    scopus 로고
    • Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    • Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
    • (2001) N Engl J Med , vol.344 , pp. 1434-1441
    • Neer, R.M.1    Arnaud, C.D.2    Zanchetta, J.R.3
  • 8
    • 0027408045 scopus 로고
    • A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones
    • Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993; 328: 833-8.
    • (1993) N Engl J Med , vol.328 , pp. 833-838
    • Curhan, G.C.1    Willett, W.C.2    Rimm, E.B.3    Stampfer, M.J.4
  • 9
    • 0031002070 scopus 로고    scopus 로고
    • Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women
    • Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126: 497-504.
    • (1997) Ann Intern Med , vol.126 , pp. 497-504
    • Curhan, G.C.1    Willett, W.C.2    Speizer, F.E.3    Spiegelman, D.4    Stampfer, M.J.5
  • 10
    • 58149390415 scopus 로고    scopus 로고
    • Calcium supplementation and incident kidney stone risk a systematic review
    • Heaney RP. Calcium supplementation and incident kidney stone risk a systematic review. J Am Coll Nutr 2008; 27: 519-27.
    • (2008) J Am Coll Nutr , vol.27 , pp. 519-527
    • Heaney, R.P.1
  • 11
    • 0014547802 scopus 로고
    • Some factors influencing the urinary excretion of oxalic acid in man
    • Zarembski PM, Hodgkinson A. Some factors influencing the urinary excretion of oxalic acid in man. Clin Chim Acta 1969; 25: 1-10.
    • (1969) Clin Chim Acta , vol.25 , pp. 1-10
    • Zarembski, P.M.1    Hodgkinson, A.2
  • 12
    • 0030052704 scopus 로고    scopus 로고
    • Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults
    • Lemann J, JR., Pleuss JA, Worcester EM, Hornick L, Schrab D, Hoffmann RG. Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults. Kidney Int 1996; 49: 200-8.
    • (1996) Kidney Int , vol.49 , pp. 200-208
    • Lemann Jr., J.1    Pleuss, J.A.2    Worcester, E.M.3    Hornick, L.4    Schrab, D.5    Hoffmann, R.G.6
  • 13
    • 84872738601 scopus 로고    scopus 로고
    • Cebm Cfebm Oxford Centre for Evidencebased Medicine - Levels of Evidence (March 2009). [updated March 2009; cited 2009 02/11/2009]
    • Cebm Cfebm Oxford Centre for Evidencebased Medicine - Levels of Evidence (March 2009). 2009 [updated March 2009; cited 2009 02/11/2009]; Available from: http://www.cebm.net/index.aspx?o=1025.
    • (2009)
  • 15
    • 18744369929 scopus 로고    scopus 로고
    • Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D ECORD) a randomised placebo-controlled trial
    • Grant AM, Avenell A, Campbell MK et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD) a randomised placebo-controlled trial. Lancet 2005; 365: 1621-8.
    • (2005) Lancet , vol.365 , pp. 1621-1628
    • Grant, A.M.1    Avenell, A.2    Campbell, M.K.3
  • 16
    • 0028264520 scopus 로고
    • A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis
    • Hasling C, Charles P, Jensen FT, Mosekilde L. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis. Osteoporos Int 1994; 4: 191-203.
    • (1994) Osteoporos Int , vol.4 , pp. 191-203
    • Hasling, C.1    Charles, P.2    Jensen, F.T.3    Mosekilde, L.4
  • 17
    • 20944432461 scopus 로고    scopus 로고
    • Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis a pilot study
    • Kaskani E, Lyritis GP, Kosmidis C et al. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis a pilot study. Clin Rheumatol 2005; 24: 232-8.
    • (2005) Clin Rheumatol , vol.24 , pp. 232-238
    • Kaskani, E.1    Lyritis, G.P.2    Kosmidis, C.3
  • 18
    • 0033710488 scopus 로고    scopus 로고
    • Parathyroid hormone as a therapy for idiopathic osteoporosis in men effects on bone mineral density and bone markers
    • Kurland ES, Cosman F, Mcmahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85: 3069-76.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 3069-3076
    • Kurland, E.S.1    Cosman, F.2    Mcmahon, D.J.3    Rosen, C.J.4    Lindsay, R.5    Bilezikian, J.P.6
  • 19
  • 20
    • 34548762125 scopus 로고    scopus 로고
    • Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide
    • Miller PD, Bilezikian JP, Diaz-Curiel M et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Met 2007; 92: 3535-41.
    • (2007) J Clin Endocrinol Met , vol.92 , pp. 3535-3541
    • Miller, P.D.1    Bilezikian, J.P.2    Diaz-Curiel, M.3
  • 21
    • 0025859536 scopus 로고
    • Effects of three different calcium preparations on urinary calcium and hydroxyproline excretion in postmenopausal osteoporotic women
    • Need AG, Horowitz M, Morris HA, Nordin BE. Effects of three different calcium preparations on urinary calcium and hydroxyproline excretion in postmenopausal osteoporotic women. Eur J Clin Nutr 1991; 45: 357-61.
    • (1991) Eur J Clin Nutr , vol.45 , pp. 357-361
    • Need, A.G.1    Horowitz, M.2    Morris, H.A.3    Nordin, B.E.4
  • 22
    • 0030449017 scopus 로고    scopus 로고
    • Correcting calcium nutritional deficiency prevents spine fractures in elderly women
    • Recker RR, Hinders S, Davies KM et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996; 11: 1961-6.
    • (1996) J Bone Miner Res , vol.11 , pp. 1961-1966
    • Recker, R.R.1    Hinders, S.2    Davies, K.M.3
  • 23
    • 70349288427 scopus 로고    scopus 로고
    • Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis
    • Yasui T, Itoh Y, Okada A et al. Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis. Urol Int 2009; 83: 226-9.
    • (2009) Urol Int , vol.83 , pp. 226-229
    • Yasui, T.1    Itoh, Y.2    Okada, A.3
  • 25
    • 0024556838 scopus 로고
    • Calcitriol treatment is not effective in postmenopausal osteoporosis
    • Ott SM, Chesnut CH, 3rd. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989; 110: 267-74.
    • (1989) Ann Intern Med , vol.110 , pp. 267-274
    • Ott, S.M.1    Chesnut 3rd., C.H.2
  • 26
    • 0033843887 scopus 로고    scopus 로고
    • Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women
    • Domrongkitchaiporn S, Ongphiphadhanakul B, Stitchantrakul W et al. Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women. Osteoporos Int 2000; 11: 486-92.
    • (2000) Osteoporos Int , vol.11 , pp. 486-492
    • Domrongkitchaiporn, S.1    Ongphiphadhanakul, B.2    Stitchantrakul, W.3
  • 27
    • 0025052617 scopus 로고
    • Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol A randomized controlled study
    • Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 1990; 113: 649-55.
    • (1990) Ann Intern Med , vol.113 , pp. 649-655
    • Gallagher, J.C.1    Goldgar, D.2
  • 28
    • 16644399512 scopus 로고    scopus 로고
    • Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest
    • Watanabe Y, Ohshima H, Mizuno K et al. Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res 2004; 19: 1771-8.
    • (2004) J Bone Miner Res , vol.19 , pp. 1771-1778
    • Watanabe, Y.1    Ohshima, H.2    Mizuno, K.3
  • 29
    • 3142757062 scopus 로고    scopus 로고
    • Alendronate inhibits urinary calcium microlith formation in a threedimensional culture model
    • Senzaki H, Yasui T, Okada A, Ito Y, Tozawa K, Kohri K. Alendronate inhibits urinary calcium microlith formation in a threedimensional culture model. Urol Res 2004; 32: 223-8.
    • (2004) Urol Res , vol.32 , pp. 223-228
    • Senzaki, H.1    Yasui, T.2    Okada, A.3    Ito, Y.4    Tozawa, K.5    Kohri, K.6
  • 30
    • 77957961364 scopus 로고    scopus 로고
    • Postmenopausal hormone use and the risk of nephrolithiasis results from the Women's Health Initiative hormone therapy trials
    • Maalouf NM, Sato AH, Welch BJ et al. Postmenopausal hormone use and the risk of nephrolithiasis results from the Women's Health Initiative hormone therapy trials. Arch Intern Med 2010; 170: 1678-85.
    • (2010) Arch Intern Med , vol.170 , pp. 1678-1685
    • Maalouf, N.M.1    Sato, A.H.2    Welch, B.J.3
  • 32
    • 0035925780 scopus 로고    scopus 로고
    • Ipriflavone in the treatment of postmenopausal osteoporosis a randomized controlled trial
    • Alexandersen P, Toussaint A, Christiansen C et al. Ipriflavone in the treatment of postmenopausal osteoporosis a randomized controlled trial. JAMA 2001; 285: 1482-8.
    • (2001) JAMA , vol.285 , pp. 1482-1488
    • Alexandersen, P.1    Toussaint, A.2    Christiansen, C.3
  • 33
    • 0026788553 scopus 로고
    • Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis
    • Agnusdei D, Adami S, Cervetti R et al. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. Bone Miner 1992; 19 (Suppl. 1): S43-8.
    • (1992) Bone Miner , vol.19 , Issue.SUPPL. 1
    • Agnusdei, D.1    Adami, S.2    Cervetti, R.3
  • 34
    • 0030789215 scopus 로고    scopus 로고
    • Efficacy of ipriflavone in established osteoporosis and long-term safety
    • Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcif Tissue Int 1997; 61 (Suppl. 1): S23-7.
    • (1997) Calcif Tissue Int , vol.61 , Issue.SUPPL. 1
    • Agnusdei, D.1    Bufalino, L.2
  • 35
    • 34347238559 scopus 로고    scopus 로고
    • Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density
    • Bonnick S, Broy S, Kaiser F et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin 2007; 23: 1341-9.
    • (2007) Curr Med Res Opin , vol.23 , pp. 1341-1349
    • Bonnick, S.1    Broy, S.2    Kaiser, F.3
  • 38
    • 33750583567 scopus 로고    scopus 로고
    • Effect of a nutritional supplementation on bone health in Chilean elderly subjects with femoral osteoporosis
    • Bunout D, Barrera G, Leiva L et al. Effect of a nutritional supplementation on bone health in Chilean elderly subjects with femoral osteoporosis. J Am Coll Nutr 2006; 25: 170-7.
    • (2006) J Am Coll Nutr , vol.25 , pp. 170-177
    • Bunout, D.1    Barrera, G.2    Leiva, L.3
  • 39
    • 21444431544 scopus 로고    scopus 로고
    • Effects of neridronate treatment in elderly women with osteoporosis
    • Cascella T, Musella T, Orio F, JR. et al. Effects of neridronate treatment in elderly women with osteoporosis. J Endocrinol Invest 2005; 28: 202-8.
    • (2005) J Endocrinol Invest , vol.28 , pp. 202-208
    • Cascella, T.1    Musella, T.2    Orio Jr., F.3
  • 41
    • 0029116697 scopus 로고
    • Alendronate treatment of the postmenopausal osteoporotic woman effect of multiple dosages on bone mass and bone remodeling
    • Chesnut CH, 3RD, Mcclung MR, Ensrud KE et al. Alendronate treatment of the postmenopausal osteoporotic woman effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144-52.
    • (1995) Am J Med , vol.99 , pp. 144-152
    • Chesnut 3rd, C.H.1    Mcclung, M.R.2    Ensrud, K.E.3
  • 42
    • 0024997302 scopus 로고
    • 17 Beta-estradiol and continuous norethisterone a unique treatment for established osteoporosis in elderly women
    • Christiansen C, Riis BJ. 17 Beta-estradiol and continuous norethisterone a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836-41.
    • (1990) J Clin Endocrinol Metab , vol.71 , pp. 836-841
    • Christiansen, C.1    Riis, B.J.2
  • 43
    • 33745034449 scopus 로고    scopus 로고
    • Intravenous ibandronate injections in postmenopausal women with osteoporosis oneyear results from the dosing intravenous administration study
    • Delmas PD, Adami S, Strugala C et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis oneyear results from the dosing intravenous administration study. Arthritis Rheum 2006; 54: 1838-46.
    • (2006) Arthritis Rheum , vol.54 , pp. 1838-1846
    • Delmas, P.D.1    Adami, S.2    Strugala, C.3
  • 44
    • 0024453944 scopus 로고
    • Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study
    • Gennari C, Agnusdei D, Gonnelli S, Nardi P. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study. Maturitas 1989; 11: 187-97.
    • (1989) Maturitas , vol.11 , pp. 187-197
    • Gennari, C.1    Agnusdei, D.2    Gonnelli, S.3    Nardi, P.4
  • 46
    • 0021220853 scopus 로고
    • Effect of calcium supplementation on urinary hydroxyproline in osteoporotic postmenopausal women
    • Horowitz M, Need AG, Philcox JC, Nordin BE. Effect of calcium supplementation on urinary hydroxyproline in osteoporotic postmenopausal women. Am J Clin Nutr 1984; 39: 857-9.
    • (1984) Am J Clin Nutr , vol.39 , pp. 857-859
    • Horowitz, M.1    Need, A.G.2    Philcox, J.C.3    Nordin, B.E.4
  • 47
    • 33646539109 scopus 로고    scopus 로고
    • Calcium and vitamin D supplementation for the prevention of fractures in postmenopausal women
    • Lee PE, Mcelhaney JE, Dian L. Calcium and vitamin D supplementation for the prevention of fractures in postmenopausal women. Aging Health 2006; 2: 241-3.
    • (2006) Aging Health , vol.2 , pp. 241-243
    • Lee, P.E.1    Mcelhaney, J.E.2    Dian, L.3
  • 48
    • 0028333585 scopus 로고
    • Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis
    • Orimo H, Shiraki M, Hayashi Y et al. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994; 54: 370-6.
    • (1994) Calcif Tissue Int , vol.54 , pp. 370-376
    • Orimo, H.1    Shiraki, M.2    Hayashi, Y.3
  • 49
    • 0026049144 scopus 로고
    • Longterm treatment of established osteoporosis with intranasal calcitonin
    • Overgaard K, Christiansen C. Longterm treatment of established osteoporosis with intranasal calcitonin. Calcif Tissue Int 1991; 49 Suppl. S60-3.
    • (1991) Calcif Tissue Int , vol.49 , Issue.SUPPL.
    • Overgaard, K.1    Christiansen, C.2
  • 50
    • 0345040227 scopus 로고    scopus 로고
    • Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis
    • Parviainen MT, Jaaskelainen K, Kroger H, Arnala I, Alhava E. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis. Clin Chim Acta 1999; 279: 145-54.
    • (1999) Clin Chim Acta , vol.279 , pp. 145-154
    • Parviainen, M.T.1    Jaaskelainen, K.2    Kroger, H.3    Arnala, I.4    Alhava, E.5
  • 51
    • 0142118462 scopus 로고    scopus 로고
    • Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass a randomized, controlled trial
    • Reginster JY, Felsenberg D, Pavo I et al. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass a randomized, controlled trial. Osteoporos Int 2003; 14: 741-9.
    • (2003) Osteoporos Int , vol.14 , pp. 741-749
    • Reginster, J.Y.1    Felsenberg, D.2    Pavo, I.3
  • 52
    • 0024467917 scopus 로고
    • Estimated long-term effect of calcitonin treatment in acute osteoporotic spine fractures
    • Resch H, Pietschmann P, Willvonseder R. Estimated long-term effect of calcitonin treatment in acute osteoporotic spine fractures. Calcif Tissue Int 1989; 45: 209-13.
    • (1989) Calcif Tissue Int , vol.45 , pp. 209-213
    • Resch, H.1    Pietschmann, P.2    Willvonseder, R.3
  • 53
    • 0025909436 scopus 로고
    • The risk of nephrolithiasis with oral calcium supplementation
    • Ringe JD. The risk of nephrolithiasis with oral calcium supplementation. Calcif Tissue Int 1991; 48: 69-73.
    • (1991) Calcif Tissue Int , vol.48 , pp. 69-73
    • Ringe, J.D.1
  • 54
    • 0034129990 scopus 로고    scopus 로고
    • Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis
    • Rossini M, Gatti D, Girardello S, Braga V, James G, Adami S. Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis. Bone 2000; 27: 119-22.
    • (2000) Bone , vol.27 , pp. 119-122
    • Rossini, M.1    Gatti, D.2    Girardello, S.3    Braga, V.4    James, G.5    Adami, S.6
  • 55
    • 0034111392 scopus 로고    scopus 로고
    • Intermittent oral disodium pamidronate in established osteoporosis a 2 year double-masked placebocontrolled study of efficacy and safety
    • Ryan PJ, Blake GM, Davie M, Haddaway M, Gibson T, Fogelman I. Intermittent oral disodium pamidronate in established osteoporosis a 2 year double-masked placebocontrolled study of efficacy and safety. Osteoporos Int 2000; 11: 171-6.
    • (2000) Osteoporos Int , vol.11 , pp. 171-176
    • Ryan, P.J.1    Blake, G.M.2    Davie, M.3    Haddaway, M.4    Gibson, T.5    Fogelman, I.6
  • 56
    • 44649084990 scopus 로고    scopus 로고
    • Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis-an Indian experience
    • Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis-an Indian experience. J Assoc Physicians India 2008; 56: 418-24.
    • (2008) J Assoc Physicians India , vol.56 , pp. 418-424
    • Sethi, B.K.1    Chadha, M.2    Modi, K.D.3    Kumar, K.M.4    Mehrotra, R.5    Sriram, U.6
  • 57
    • 4544222260 scopus 로고    scopus 로고
    • A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)
    • Shiraki M, Fukunaga M, Kushida K et al. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int 2003; 14: 225-34.
    • (2003) Osteoporos Int , vol.14 , pp. 225-234
    • Shiraki, M.1    Fukunaga, M.2    Kushida, K.3
  • 58
    • 28844485113 scopus 로고    scopus 로고
    • Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis
    • Tekeoglu I, Adak B, Budancamanak M, Demirel A, Ediz L. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis. Rheumatol Int 2005; 26: 157-61.
    • (2005) Rheumatol Int , vol.26 , pp. 157-161
    • Tekeoglu, I.1    Adak, B.2    Budancamanak, M.3    Demirel, A.4    Ediz, L.5
  • 59
    • 0029972851 scopus 로고    scopus 로고
    • Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis
    • Thamsborg G, Jensen JE, Kollerup G, Hauge EM, Melsen F, Sorensen OH. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 1996; 18: 207-12.
    • (1996) Bone , vol.18 , pp. 207-212
    • Thamsborg, G.1    Jensen, J.E.2    Kollerup, G.3    Hauge, E.M.4    Melsen, F.5    Sorensen, O.H.6
  • 60
    • 0025265644 scopus 로고
    • Low-dose calcitriol versus calcium in established postmenopausal osteoporosis
    • Tilyard M. Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism 1990; 39 (Suppl. 1): 50-2.
    • (1990) Metabolism , vol.39 , Issue.SUPPL. 1 , pp. 50-52
    • Tilyard, M.1
  • 61
    • 0036183610 scopus 로고    scopus 로고
    • A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis effects on bone mineral density and bone markers
    • Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis effects on bone mineral density and bone markers. J Bone Miner Res 2002; 17: 521-7.
    • (2002) J Bone Miner Res , vol.17 , pp. 521-527
    • Trovas, G.P.1    Lyritis, G.P.2    Galanos, A.3    Raptou, P.4    Constantelou, E.5
  • 62
    • 0035139987 scopus 로고    scopus 로고
    • Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis
    • Zegels B, Eastell R, Russell RG et al. Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis. Bone 2001; 28: 108-12.
    • (2001) Bone , vol.28 , pp. 108-112
    • Zegels, B.1    Eastell, R.2    Russell, R.G.3
  • 63
    • 36749072147 scopus 로고    scopus 로고
    • Limited effect of calcium and vitamin D in reducing osteoporotic fractures
    • Limited effect of calcium and vitamin D in reducing osteoporotic fractures. Australian Journal of Pharmacy 2007; 88: 90-1.
    • (2007) Australian Journal of Pharmacy , vol.88 , pp. 90-91


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.